Pharvaris N.V. (NASDAQ:PHVS) Short Interest Up 48.7% in August

Pharvaris N.V. (NASDAQ:PHVS) saw a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 1,775,021 shares, an increase of 48.7% from the July 30th total of 1,193,401 shares. Based on an average trading volume of 638,201 shares, the days-to-cover ratio is presently 2.8 days. Currently, 2.7% of the shares of the stock are short sold.

Pharvaris Stock Performance

NASDAQ PHVS traded down $0.13 during trading hours on Tuesday, reaching $34.48. The company’s stock had a trading volume of 209,450 shares, compared to its average volume of 338,093. The stock has a market cap of $2.26 billion, a PE ratio of -11.33 and a beta of -2.31. Pharvaris has a fifty-two week low of $20.65 and a fifty-two week high of $38.13. The company’s 50-day moving average is $34.64 and its two-hundred day moving average is $30.82.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Equities analysts expect that Pharvaris will post -3.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Pharvaris news, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $34.77, for a total transaction of $79,692.84. Following the sale, the chief executive officer directly owned 130,625 shares in the company, valued at approximately $4,541,831.25. The trade was a 1.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88. Following the transaction, the director directly owned 315,167 shares in the company, valued at approximately $11,185,276.83. This trade represents a 8.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 121,325 shares of company stock worth $4,270,425 in the last ninety days.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of PHVS. Geode Capital Management LLC lifted its stake in Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after buying an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc raised its holdings in shares of Pharvaris by 17.2% in the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi lifted its position in shares of Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after acquiring an additional 27,416 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after acquiring an additional 7,879 shares in the last quarter.

Wall Street Analyst Weigh In

PHVS has been the topic of several recent analyst reports. UBS Group set a $74.00 target price on shares of Pharvaris in a research report on Wednesday, May 13th. Royal Bank Of Canada boosted their price target on Pharvaris from $51.00 to $52.00 and gave the stock an “outperform” rating in a research note on Thursday, August 13th. Citigroup restated a “market outperform” rating on shares of Pharvaris in a report on Thursday, August 13th. Wall Street Zen downgraded Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Pharvaris currently has an average rating of “Moderate Buy” and an average price target of $51.08.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.